Lorvotuzumab mertansine
Encyclopedia
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate
of lorvotuzumab linked to mertansine
intended for CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer
).
It has been granted Orphan drug
status for Merkel cell carcinoma
.
It has reported encouraging Phase II results for small-cell lung cancer.
Antibody-drug conjugate
Antibody-drug conjugates are a new type of targeted therapy, used for example for cancer. They consist of an antibody linked to a payload drug . Hence, they are a type of immunoconjugate and often an immunotoxin.The antibody causes the ADC to bind to the target cancer cells...
of lorvotuzumab linked to mertansine
Mertansine
Mertansine is a cytotoxic agent also known as DM1. It is a maytansinoid .Its patent rights are owned by ImmunoGen Inc.- Uses :...
intended for CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer
Ovarian cancer
Ovarian cancer is a cancerous growth arising from the ovary. Symptoms are frequently very subtle early on and may include: bloating, pelvic pain, difficulty eating and frequent urination, and are easily confused with other illnesses....
).
It has been granted Orphan drug
Orphan drug
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease...
status for Merkel cell carcinoma
Merkel cell carcinoma
Merkel cell carcinoma Merkel cell carcinoma Merkel cell carcinoma (also known as a "Cutaneous apudoma," "Primary neuroendocrine carcinoma of the skin," "Primary small cell carcinoma of the skin," and "Trabecular carcinoma of the skin"...
.
It has reported encouraging Phase II results for small-cell lung cancer.